Kelvin Moses, MD, PhD, reflects on exciting data in metastatic prostate cancer treatment presented at the American Urological Association 2024 Annual Meeting in San Antonio, Texas. Theranostics, particularly lutetium-based prostate-specific membrane antigen (PSMA) radionuclide therapy, showed promise in metastatic castration-resistant prostate cancer. The RESIST-PC phase 2 trial demonstrated significant prostate-specific antigen (PSA) reduction and impressive response rates in patients with progressive disease.
In addition, the PSMAfore trial indicated improved radiographic progression-free survival and PSA decline in patients compared with standard treatment — and importantly, metastasis-directed therapy, especially stereotactic body radiation therapy in oligometastatic disease, exhibited potential for improving overall survival. These findings underscore the emergence of well-tolerated therapies with significant clinical benefits in advanced prostate cancer.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AUA 2024: Insights on Emerging Therapies in Metastatic Prostate Cancer - Medscape - May 21, 2024.
Comments